Follow up with last post;
Credit Suisse's U.S. analysts start coverage of Mesoblast (MSB.AU, MESO) with a US$10 price target on its Nasdaq-listed shares, near double the US$5.13 last trade. "We see the opportunity for one or two late-stage programs that could have potential blockbuster assets," says Credit Suisse. "We think current shares are trading with little credit to future programs." Mesoblast has three late-stage programs: graft versus host disease, congestive heart failure in partnership with Teva, and chronic lower back pain due to disc degeneration. Credit Suisse thinks the heart and back program can lead to big royalties. "There is no partner in the back program, but we model one paying 25% since it is such a big opportunity." If both programs work, the broker's value estimate is US$24. ([email protected]; @beckthurlow)
- Forums
- ASX - By Stock
- MSB
- Ann: Change in substantial holding
Ann: Change in substantial holding, page-12
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | $1.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 75212 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 1.185 |
1 | 20000 | 1.175 |
1 | 5664 | 1.170 |
1 | 17568 | 1.160 |
3 | 56695 | 1.150 |
Price($) | Vol. | No. |
---|---|---|
1.190 | 59712 | 2 |
1.195 | 36255 | 5 |
1.200 | 404381 | 31 |
1.205 | 3000 | 1 |
1.210 | 162475 | 7 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
MSB (ASX) Chart |